Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Sandoz Group
(OTCQX:SDZNY)
Intraday
$34.72
-0.77
[-2.17%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$34.72
-0.77
[-2.17%]
Last update: 10:28AM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Sandoz Group Stock (OTC:SDZNY)
Sandoz Group Stock (OTC: SDZNY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, May 22, 2024
Sandoz Obtains European Commission Approval For Wyost And Jubbonti, The First And Only Biosimilars Of Denosumab In Europe
Benzinga Newsdesk
-
May 22, 2024, 1:13AM
Tuesday, May 07, 2024
Sandoz Q1 Sales $2.492B Up From $2.384B YoY
Benzinga Newsdesk
-
May 7, 2024, 3:11AM
Tuesday, April 30, 2024
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Vandana Singh
-
Apr 30, 2024, 11:54AM
Sandoz And Amgen Resolve Patent Disputes Over FDA-Approved Denosumab Biosimilars In The US
Benzinga Newsdesk
-
Apr 30, 2024, 3:56AM
Monday, April 22, 2024
Sandoz Gains European Commission Approval For Pyzchiva (ustekinumab), Strengthening Immunology Offering
Benzinga Newsdesk
-
Apr 22, 2024, 2:45AM
Wednesday, March 13, 2024
Sandoz For 2024 Expects Net Sales To Grow Mid-Single Digit In Constant Currencies YoY, And Core EBITDA Margin Around 20%
Benzinga Newsdesk
-
Mar 13, 2024, 2:30AM
Sandoz Fiscal 2023 Core EPS $2.20 Down From $2.83 YoY; Sales $9.65B Up From $9.07B YoY
Benzinga Newsdesk
-
Mar 13, 2024, 2:28AM
Friday, March 08, 2024
Beigene Said It Filed Patent Infringement Suits Against Sandoz, MSN Pharmaceuticals
Charles Gross
-
Mar 8, 2024, 6:09AM
Tuesday, March 05, 2024
FDA Approves JUBBONTI By SANDOZ INC
Benzinga Newsdesk
-
Mar 5, 2024, 10:26AM
Thursday, February 29, 2024
Generic/Biosimilar Player Sandoz Settles US Price Fixing Case For $265M
Vandana Singh
-
Feb 29, 2024, 11:19AM
Wednesday, January 31, 2024
Sandoz Launches First And Only Biosimilar For Multiple Sclerosis, Tyruko® In Germany
Benzinga Newsdesk
-
Jan 31, 2024, 2:54AM
Monday, January 22, 2024
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?
Vandana Singh
-
Jan 22, 2024, 9:41AM
CORRECTION: Coherus To Divest Ophthalmology Franchise To Sandoz In $170M Cash Deal
Benzinga Newsdesk
-
Jan 22, 2024, 7:15AM
Coherus To Divest Ophthalmology Franchise To Sandoz In $170M Cash Deal
Benzinga Newsdesk
-
Jan 22, 2024, 1:44AM
Monday, December 04, 2023
Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases
Vandana Singh
-
Dec 4, 2023, 2:02PM
Tuesday, November 28, 2023
Novartis Outlines Pure-Play Strategy Progress After Generics Business Spin-Off
Vandana Singh
-
Nov 28, 2023, 10:55AM
Friday, November 10, 2023
Sandoz Inaugurates New Antibiotic Production Plant In Austria And New Biosimilar Development Center In Germany
Benzinga Newsdesk
-
Nov 10, 2023, 8:15AM
Tuesday, October 24, 2023
Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More
Lekha Gupta
-
Oct 24, 2023, 5:53AM
Wednesday, October 04, 2023
Novartis Shares Decline As Spin Off Sandoz's Market Debut Falls Short of Expected Valuation
Vandana Singh
-
Oct 4, 2023, 12:35PM
Novartis Earlier Announced it Completed The Spin-off Of Sandoz Unit; U.S. Sandoz ADRs To Trade Under Symbol 'SDZNY'
Charles Gross
-
Oct 4, 2023, 4:46AM